Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

NCT00946283 - Lacticaseibacillus rhamnosus GG (LGG) & Acute graft-versus-host disease (acute GVHD)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Background:

Graft-versus-host disease (GVHD) is a significant adverse effect linked to allogeneic stem cell transplants. Research conducted on mice has shown that administering the probiotic Lacticaseibacillus rhamnosus GG (LGG) may decrease the occurrence of GVHD following a hematopoietic stem cell transplant (1).

Study overview:

NCT00946283 - Lacticaseibacillus rhamnosus GG (LGG) & Post allogeneic stem cell transplantation (SCT) is a randomized clinical trial studying Lacticaseibacillus rhamnosus GG (LGG) in patients undergoing donor stem cell transplant for hematologic cancer or myelodysplastic syndrome (1)

Primary outcome measures:

Safety as indicated by the lack o…

References (Sources)

Lactobacillus rhamnosus GG probiotic enteric regimen does not appreciably alter the gut microbiome or provide protection against GVHD after allogeneic hematopoietic stem cell transplantation
Gorshein et al. 2017

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!